Sarepta Therapeutics, Inc. (SRPT)
Current
- (-)
After Hours
Rating Performance
Rating Return
-8.22% vs
Rating Accuracy
0% (0 of 1*)
Rating Return
-8.22% vs
Rating Accuracy
0% (0 of 1*)
Rating Return
-8.22% vs
Rating Accuracy
0% (0 of 1*)
Rating Return
-8.22% vs
Rating Accuracy
0% (0 of 1*)
FV Performance
FV Accuracy
0 Hits (0% Hit Rate)
FV Avg. Distance
-25.08%
FV Accuracy
5 Hits (41.67% Hit Rate)
FV Avg. Distance
-20.39%
FV Accuracy
5 Hits (26.32% Hit Rate)
FV Avg. Distance
-20.39%
FV Accuracy
5 Hits (11.63% Hit Rate)
FV Avg. Distance
-17.63%
About
CEO
Douglas S. Ingram
Employees
743
Industry
Neurology Biopharmaceuticals
Sector
Healthcare
Headquarters
Cambridge
Exchange
NASDAQ
Summary Stats
Market Cap
11.8B
Revenue
933M
Net Income
-703M
EPS
-$8.03
Price-to-Earnings
-16.68
Price-to-Book
30.6
Debt-to-Equity
7.13
News
Analyst Ratings
Price targets projected by 21 analysts
High
$217.00
Average
$188.38
Low
$140.00
Ratings calculated by 23 analysts
Buy
20
Hold
3
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q4 2022
Above by $0.82
-$0.53 +60.7%
-1.35
-0.77
Up 31%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--